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hallucinations (AVATAR therapy): study
protocol for a randomised controlled trial
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Abstract
Background: Psychological interventions which adopt an explicitly interpersonal approach are a recent
development in the treatment of distressing voices. AVATAR therapy is one such approach which creates a direct
dialogue between a voice-hearer and a computerised representation of their persecutory voice (the avatar) through
which the person may be supported to gain a sense of greater power and control. The main objective of the trial is
to test the clinical efficacy of this therapy to reduce the frequency and severity of auditory verbal hallucinations
(AVH). Secondary objectives of the study are to explore explanatory mechanisms of action and potential
moderators, to carry out a qualitative evaluation of participants’ experience and to conduct an economic
evaluation.
Methods/Design: The AVATAR randomised clinical trial will independently randomise 142 participants to receive
either 7 sessions of AVATAR therapy or supportive counselling (SC). The study population will be individuals with
schizophrenia spectrum and other psychotic disorders who report hearing persistent distressing voices, for more
than 12 months, which are unresponsive or only partially responsive to antipsychotic medication. The main
hypotheses are that, compared to SC, AVATAR therapy will reduce the frequency and severity of AVH and will also
reduce the reported omnipotence and malevolence of these voices. Assessments will occur at 0 weeks (baseline),
12 weeks (post-intervention) and 24 weeks (follow-up), and will be carried out by blinded assessors. Both
interventions will be delivered in a community-based mental health centre. Therapy competence and adherence
will be monitored in both groups. Statistical analysis will follow the intention-to-treat principle and data will be
analysed using a mixed (random) effects model at each post treatment time point separately. A formal mediation
and moderator analysis using contemporary causal inference methods will be conducted as a secondary analysis.
The trial is funded by the Welcome Trust (WT).
Discussion: AVATAR therapy showed promising effects in a pilot study, but the efficacy of the approach needs to
be examined in a larger randomised clinical trial before wider dissemination and implementation in mental health
services.
Trial registration: Current Controlled Trials ISRCTN: 65314790, registration date: 27 March 2013.
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Background
Previous studies have shown that around 70 % of people
with schizophrenia report auditory hallucinations [1].
Voice hearing or auditory verbal hallucination (AVH) is
the most commonly reported form of auditory hallucina-
tions [2, 3] and is typically defined as hearing a voice or
other sound in the absence of an external stimulus [4].
These AVHs frequently provoke high levels of distress
and interference in the daily lives of those who experi-
ence them and, therefore, have become a major target of
psychological therapies for psychosis [5].
Drawing on seminal early work from Chadwick and
Birchwood, cognitive models of voice- hearing propose
that beliefs about voices (specifically regarding identity,
power, intention and control) are key to understanding
distress and maladaptive responding [6, 7]. In their
model, Morrison and colleagues specifically propose that
auditory hallucinations occur when a person misattrib-
utes an internal experience (e.g. intrusive thought) to an
external source [8]. It is argued that subsequent maladap-
tive appraisal processes are maintained by safety behav-
iours (including selective attention), faulty self-knowledge
(including metacognition), social knowledge, mood and
physiology [9]. Birchwood and colleagues [10, 11] devel-
oped their model by applying social rank theory [12, 13]
to voice-hearing and found that individuals who
experienced powerlessness and inferiority in social rela-
tionships were more likely to report similar experiences
during the voice interaction [10, 14]. It is argued that
early powerlessness and perceived inferiority in social re-
lationships establish social schemata that drive subse-
quent appraisals of voices leading, in turn, to significant
levels of distress and depression [11]. Recent reviews have
provided support for the proposal that social schema may
mediate the appraisal-distress relationship with the impli-
cation that therapies could benefit from targeting social
and interpersonal variables [2, 14].
These theoretical developments have informed a specific
cognitive therapy for command hallucinations [15, 16]. A
randomised controlled trial of this approach [15] has
recently reported a reduction in the rate of compliance
compared with the treatment as usual group (odds ratio
0·45) along with an associated reduction in the specific
treatment target (the power difference between the per-
ceived threat of the voice and the hearer’s ability to miti-
gate this threat). Other approaches have also adopted an
explicitly relational approach, targeting key aspects of the
voice relationship including appraisals of relative power
and assertiveness [17, 18].
More recently, AVATAR therapy has been developed
as a relational approach by Professor Julian Leff [19, 20].
This builds on the previous theoretical and clinical
Fig. 1 Study flowchart
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developments within the context of a novel therapeutic
milieu. The main goal of this therapy is to facilitate a
dialogue between the patient and a computerised repre-
sentation of their persecutory voice in which the voice
hearer is assisted to gain control over the distressing
voice. The approach uses computer technology devel-
oped by the Speech, Hearing and Phonetics Department
at University College London which enables each partici-
pant to create a visual representation of the entity (hu-
man or non-human) that they believe is talking to them.
Additional software is used to transform the voice of the
therapist to match closely the pitch and tone of the voice
the patient reports hearing, the two processes finally
being combined to produce a computer simulation (a
virtual agent or ‘avatar’) through which the therapist can
interact with the participant. The therapist promotes a
dialogue between the participant and the avatar in which
the avatar progressively comes under the participant’s
control. The sessions are audio- recorded and provided
to the participant on an MP3 player for continued use at
home [19].
Pilot study
In an initial pilot study, comparing the therapy with a
waiting list control group, a maximum of 7 sessions
lasting 30 minutes resulted in highly significant reductions
in the participants’ hallucinations and associated distress,
as well as a reduction in scores on the omnipotence and
malevolence subscales in the Revised version of the Beliefs
about Voices Questionnaire (BAVQ-R) [19].
Researchers in the pilot study asked the participants
how close a match there was between the image on the
monitor or the voice they had selected and what they
believed their persecutor looked and sounded like. Rat-
ings of the match were not reported or explored as pos-
sible treatment moderators but two participants said the
avatar was not a good representation of their hallucin-
ation [20]. In terms of feasibility, of the twenty-seven
people referred to the trial, one declined consent, four
withdrew before therapy commenced and five did not
complete the total course of the therapy.
In light of the encouraging results, the next step is to
test the therapy’s efficacy in a larger methodologically
rigorous clinical trial, in which a comparison is made
between AVATAR therapy and a control condition, in
order to take account of non-specific elements of ther-
apy exposure, before wider dissemination of the therapy
approach.
While the pilot did not include a formal mediation ana-
lysis, putative mechanisms emerge from the key treatment
‘phases’. Within the first phase the participants’ key task is
to develop assertiveness with the avatar’s character grad-
ually changing to become conciliatory or even helpful in
line with the increasing strength and confidence of the
person. Commonalities with Cognitive Therapy for Com-
mand Hallucinations [16, 15] and other relational ap-
proaches [17] along with the pilot findings, suggest that
changes in beliefs about voices (specifically related to
omnipotence and malevolence) and appraisal of the voice
relationship (specifically relative power and assertiveness)
are likely mechanisms of action. The second phase specif-
ically targets improvements in self-concept and develop-
ment of a more positive identity, work that is consistent
with recent approaches emphasising the importance of
self-esteem and self-compassion in working with distres-
sing voices [21, 22]. Finally, given that anxiety processes
Fig. 2 Examples of avatars
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are seen as central in the maintenance of distressing
voices [9] and that AVATAR therapy involves an exposure
to a distressing stimulus (voice content and image), reduc-
tions in anxiety may also be an important mechanism of
action. With regards to potential moderators, engagement
with, and therapeutic response to, cognitive behaviour
therapy for psychosis have been predicted by baseline
beliefs about illness [23] and social factors such as pres-
ence of a caregiver [24]. Given the novelty of the set-up
AVATAR therapy may also have more specific treatment
moderators. The task of creating a single avatar to rep-
resent the person’s voice experience, incorporating dis-
cernible verbatim content, suggests that the number of
voices, type of content and ratings of the created voice/
image may act as additional moderators.
Research objectives and hypotheses
The trial has three main objectives:
1. To test the clinical efficacy of the therapy compared
to supportive counselling (SC).
2. To determine preliminary estimates of cost-
effectiveness of the AVATAR therapy.
3. To explore explanatory mechanisms of action as
well as moderators for AVATAR therapy.
The trial hypotheses are:
a) AVATAR therapy will be more effective in reducing
the frequency and severity of auditory
hallucinations, in comparison to SC.
b) AVATAR therapy will be more effective in reducing
the reported omnipotence and malevolence of
auditory hallucinations, in comparison to SC.
c) The improvements attributable to AVATAR therapy
will be maintained at 24 weeks follow-up.
d) AVATAR therapy will be more cost-effective than
SC.
e) The mediators of treatment effects for AVATAR
therapy on changes in auditory hallucinations will be
beliefs about voices (specifically omnipotence and
malevolence), beliefs about the self (improved self-
esteem), appraisal of voice relationship (specifically
relative power and assertiveness), and reduction in
anxiety.
The moderators of the treatment effects for AVATAR
therapy will be number of voices, type of content (de-
rogatory versus non-derogatory), ratings of the created
voice/image, beliefs about problems and social support.
Methods/Design
The study design is a single blind randomised controlled
trial. Patients who meet inclusion criteria (see below)
will be independently randomised to receive either 7
sessions of AVATAR therapy or SC (see Fig. 1). Both
groups will continue to receive standard psychiatric care.
Written consent will be obtained from each eligible par-
ticipant prior to assessment and randomisation. Partici-
pants will be allocated to conditions using randomised
permuted blocks (with a block size randomly varying be-
tween 2 and 6). The block sizes will not be disclosed to
ensure allocation concealment. Randomisation will be
carried out at the point of consent through an independ-
ent web-based service provided by the UKCRC Regis-
tered Clinical Trials Unit (CTU) at King’s College
London (Registration Number 053). The randomisation
will be conducted by the CTU in order to keep the data
management and the statistician blind to the study con-
dition. Assessments will be conducted by research asses-
sors blind to therapy allocation. In case of unblinding,
the trial coordinator will switch assessors for follow-up
assessments. The reliability of the raters on the assess-
ment battery will be formally assessed. For reporting the
trial, the Consolidated Standards of Reporting Trials
(CONSORT) with the extension for non-pharmacologic
treatment and the Recommendations for Interventional
Trials (SPIRIT) guidelines will be followed [25]. All data
collected and study-related information will be stored
securely at the Institute of Psychiatry, Psychology and
Neuroscience, King’s College, London.
Participants
The inclusion criteria are as follows: 1) aged over 18
years; 2) have experienced troubling auditory hallucina-
tions for at least 12 months; 3) primary diagnosis of
non-organic psychosis (including International Classifi-
cation of Diseases (ICD)-10 categories F20-29 and F30-
39, subcategories with psychotic symptoms). Criteria for
exclusion are as follows: 1) unable to give informed
consent; 2) currently in receipt of cognitive behaviour
therapy for psychosis or attending a group specific to
hearing voices; 3) unable to identify a single dominant
voice to work on; 4) refusing all medication; 5) a diagno-
sis of organic brain disease; 6) a primary substance
dependency; 7) auditory hallucinations in a language not
spoken by the therapists; 8) a command of spoken
English inadequate for engaging in therapy; 9) inability
to tolerate the assessment process.
Clinical staff will be informed of the study and basic
criteria for inclusion and asked to refer patients who ex-
press an interest in taking part. Patients are also able to
self-refer in response to information given to primary
care centres and in response to posters in the relevant
clinical areas of the Trust. The majority of the referrals
will be received from the South London and Maudsley
National Health Service (NHS) Foundation Trust. How-
ever, for the patients who are not currently within South
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London and Maudsley (SLaM) services, we will follow
Patient Identification Centre (PICs: Health Boards or
Trusts, which can identify possible participants for the
study) activity procedure. Finally, other clinicians work-
ing in Mental Health Services in the UK who are aware
of the study via clinical contacts or conferences con-
ducted by the research team can also refer participants.
All referrals will be screened for eligibility. Participants’
diagnosis will be confirmed by an independent experi-
enced and trained psychiatrist examining medical case
notes and using the OPCRIT system [26].
Planned interventions
Eligible participants will be randomised to either the AVA-
TAR therapy or SC arm of the trial. AVATAR therapy and
SC will both be delivered over 7 (1 introductory session
plus 6 therapy) sessions lasting approximately 45 minutes.
Both therapies will be manualised and trial therapists
provided with training and on-going supervision. Therapy
sessions will be audio-recorded and assessed for therapy
competence and adherence to the treatment model. Par-
ticipants allocated to SC will have the opportunity to re-
ceive AVATAR therapy at the end of the trial.
AVATAR therapy
Participants first create a computerised representation of
the person or entity that they feel represents the source
of their voices (see Fig. 2). Over the following sessions
the therapist facilitates a direct dialogue between the
person and the avatar they have created, in which the
therapist voices the avatar’s speech. The system is set up
in two rooms in the same building with two linked com-
puters. Participants sit in one room facing the monitor
on which the avatar appears. The therapist sits in a sec-
ond room facing the monitor with a control panel that
allows them to talk to the participant in their own voice
or in the morphed avatar voice. The therapist can see
and hear everything that is appearing on the participant’s
monitor as well as the participant’s responses, adjusting
therapeutic interventions and response to the avatar ac-
cording to the unfolding dialogue. Should the participant
be distressed at any point they can press a button on the
desk that will terminate the session, replacing the on-
screen avatar with a pleasant scene. The therapist also
uses his/her judgement to anticipate distress and modify
the avatar interaction accordingly. For more details on
the software used in AVATAR therapy please see Leff
et al. [19].
After completing the creation of the avatar (intro-
ductory session), the therapy is delivered in 6 weekly
45-minute sessions of which up to 20 minutes involves
face-to-face work with the avatar and the remaining
time is spent with the therapist and participant in dir-
ect contact both assessing current voices and planning
the AVATAR session and subsequently debriefing on it.
The number and progress of sessions is determined by
a discussion with the participant at each session con-
cerning any change in severity, content, malevolence
or frequency of the hallucinations. Therapy will be
terminated before six sessions if the participant has re-
ported complete absence of any voices for at least three
consecutive sessions. The total number of sessions can
be extended by up to three further sessions where there is
a clear rationale for the likely benefit of additional
sessions, such as evidence of delayed and ongoing im-
provements during later sessions, on self-reported sever-
ity, content, malevolence or frequency of the voice (any
additional sessions are agreed by consensus within the
therapy team). Evidence of any adverse reactions will re-
sult in completion of an adverse events form (see safety
assessment section below). Evidence of any adverse reac-
tions to therapy will be closely monitored. Therapy will be
terminated in the event of any significant deterioration in
mental state which renders the continuation of therapy
inadvisable (for example where the therapy sessions are
associated with significant increased distress and/or risk of
harm to self/others); and any such termination would be
decided through agreement between therapist (in consult-
ation with the AVATAR therapy team), the participant
and the relevant clinical team. All therapists delivering
AVATAR therapy have at least 5 years of clinical experi-
ence in psychosis and have been trained by Professor
Julian Leff on delivery of the therapy.
Supportive counselling
The control condition comprises a manual-based, face-
to-face, SC approach based on the manual used in the
SOCRATES clinical trial [27] to control for non-
specific elements of therapy exposure. It will be deliv-
ered over the same number and duration of sessions
(including application of the same rules for early ter-
mination and extension as above), with the aim of
matching the duration of total therapist contact time to
that in the AVATAR arm.
Audio-recordings
All therapy sessions are audio-recorded, with partici-
pants’ consent. The participant is provided with an
audio-recording of the session on an MP3 player with
instructions to listen at times of their choosing between
sessions (for those in the AVATAR arm the recording is
the dialogue with the avatar, for those in the SC arm the
recording is a summary of the key points from the
session).
Assessments and follow-up
There are 3 assessment points: at baseline before ran-
domisation, at 12 and 24 weeks. All measures apart from
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weekly in-session measures will be carried out by trained
research staff. Participants will complete a number of
self-completed and interview-based measures to assess
the impact of interventions on outcomes and to explore
potential mediators and moderators of therapy. All the
assessment sessions will be audio-recorded to ensure the
accuracy of data collection. The participants will be
reimbursed £20 plus any travel expenses for each assess-
ment session in recognition of their time and other out-
of-pocket expenses.
Measures
The primary outcome measure of the study is the total
score on the auditory hallucinations subscale of the
Psychotic Symptoms Rating Scale (PSYRATS-AH [28])
at the 12-week follow-up. It is an interviewer-assessed
measure of the frequency and duration of auditory hal-
lucinations over an average week. The PSYRATS is spe-
cifically designed for use with people suffering from
psychosis, with inter-rater reliability ranging from 0.79
to 1.00 and high validity when compared with similar
psychiatric scales [28]. It has been extensively used in
research with these populations and has been shown to
be acceptable to service users.
Secondary outcome measures will include the Revised
version of the Beliefs about Voices Questionnaire (BAVQ-
R, [29]: a self-report measure which focuses on the
patient’s beliefs about the voices, and indexes how likely
the voices are to affect behaviour. In addition to the total
score, changes in two subscales will be analysed: omnipo-
tence and malevolence.
Other standardised measures will be used to assess
changes in voice experience and appraisals: the Voice
Acceptance and Action Scale: VAAS [30] and Voice
Power Differential Scale: VPDS [10]. We will assess
changes in delusions using the Psychotic Symptoms
Rating Scale: PSYRATS-D [28] and other psychotic
symptoms using the Scale for Assessment of Positive
and Negative Symptoms: SAPS and SANS [31]. Other
standardised questionnaires will assess anxiety and
depression (Depression Anxiety and Stress Scale: DASS-
21 [32]; (Calgary Depression Scale [33]); self-esteem
[34]; quality of life (Short Assessment of Quality of Life,
MANSA [35]); and illicit drug use [36].
In order to assess progress during the therapy, the
PSYRATS-AH [28] and the VPDS [10] will be com-
pleted by the therapist and the participant at each ther-
apy session. Additionally, an adapted version of the
Sense of Presence Questionnaire [37], the State Social
Paranoia Scale [38] in relation to the avatar along with
analogical scales will be used to assess the participant’s
interaction with the avatar and the match obtained dur-
ing the creation of the image/voice. Burns Empathy
Scale [39] will be completed in sessions 2, 4 and 6. All
the questionnaires in the study are being delivered in
paper-and-pencil format.
Assessment of safety
Serious adverse events will be monitored and recorded
throughout the study period, as well as complaints about
therapy. The following are considered as adverse events:
1) hospital admissions; 2) home treatment team involve-
ment; 3) suicide attempts; 4) any violent incident neces-
sitating police involvement (whether victim or accused);
5) self-harming behaviour; 6) all deaths. Furthermore,
the trial coordinator will review all participant clinical
notes and contact clinicians for any important additional
information. These events are reported to the Data
Monitoring and Ethics Committee (DMEC) of the trial.
Participants have the right to withdraw from the study
at any time.
Sample size
We will recruit 142 participants to the trial, approxi-
mately 71 in each arm. The sample size calculation is
based on the primary outcome measure of a reduction
in the severity of auditory hallucinations as measured by
the total score of the Auditory Hallucinations compo-
nent of the Psychotic Symptoms Rating Scale (PSY-
RATS). Compared with treatment as usual, a clinically
meaningful change in the total PSYRATS score is 5
units, which corresponds to an effect size of approxi-
mately d = 0.8, whereas supportive therapy typically
achieves a modest effect of d = 0.2. Our sample size of
71 in each group will have 90 % power to detect an
effect size of 0.6 using a two-group t test with a 0.05
two-sided significance level while also allowing for a 20 %
loss to follow-up. In practice, the power will be increased
by using a mixed (random) effects model allowing for
baseline covariates (rather than a simple t test) to gain
precision in the effect estimates.
Analysis
Statistical analysis
Analysis will be conducted in Stata version 13 (Stata-
Corp, College Station, TX, USA) [40]. Descriptive sta-
tistics within each randomised group will be presented
for baseline values. These will include counts and per-
centages for binary and categorical variables and means
and standard deviations, or medians with lower and
upper quartiles, for continuous variables, along with
minimum and maximum values and counts of missing
values. There will be no tests of statistical significance
or confidence intervals for differences between rando-
mised groups on any baseline variable.
The primary hypothesis for change in the severity
of auditory hallucinations as measured by the total
PSYRATS-AH score will be analysed using a mixed
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(random) effects model allowing for the baseline measure-
ment of PSYRATS-AH and treatment assignment as fixed
effects, at 12 weeks. This takes account of missing out-
comes assuming a missing at random mechanism which
allows missingness to depend on baseline severity of AH
and treatment assignment. Therapist effects will be mod-
elled by including a random effect for each therapist in
the two therapy conditions. The use of a mixed (random)
effect models will allow for estimation of the intra-cluster
correlation coefficient, a measure of the proportion of
variance in outcome because of therapist effects, which
can be used in future applications; no estimate of this is
currently available. Secondary outcome measures will be
analysed using the same modelling approach. This in-
cludes analysis of the primary outcome and secondary
outcomes at 24 weeks.
A secondary mediation analysis will investigate puta-
tive mediational factors (including beliefs about voices,
self-esteem, anxiety/levels of distress) using modern
causal inference methods. This involves using paramet-
ric regression models to test for mediation of the AVA-
TAR therapy on AH through the putative mediators.
Analyses will adjust for baseline measures of the medi-
ator, outcomes, and possible measured confounders.
We will include repeated measurement of mediators
and outcomes to account for classical measurement
error and baseline confounding, and instrumental vari-
able methods (baseline covariate by randomisation in-
teractions as potential instruments) to investigate the
sensitivity of the estimates to these problems and that
of unmeasured confounding [41].
Moderators will be assessed separately by repeating
the primary analysis models and including interaction
terms between the randomised intervention and each
moderator. The coefficient of the interaction term is a
measure of whether the treatment effect differs between
levels of the moderator.
Qualitative evaluation
A qualitative evaluation of participants’ experience of
therapy will be carried out to explore the processes of
implementation of the AVATAR therapy, and partici-
pants’ perception of the intervention as appropriate to
addressing their auditory hallucinations and to explore
barriers and facilitators of therapy. It will be based on an
individual semi-structured interview using a topic guide.
Questions will focus on the participants’ experience of
using the computer software, their views on how ‘realis-
tic’ they found the avatar to be and their opinion as to
how important this is, the environment in which the
intervention is offered and duration of sessions. Other
external aspects related to the intervention, such as use
of the MP3 players between sessions and facilitators to
the delivery of the intervention, will be also explored.
Participants will also be asked how their experience of
therapy has affected their views about their voices, and
their views about how well they will manage their voices
in the future.
Independent qualitative interviews will be also con-
ducted with the trial therapists in order to gather their
impressions of conducting the sessions, the challenge of
enacting the avatar, and their experience of group super-
vision. This will help refine therapies and for implemen-
tation purposes.
Health economic analysis
Service use will be measured for a retrospective 3-month
period at baseline and 12-week and 24-week follow-up
using the Client Service Receipt Inventory [42]. Service
use will be measured comprehensively and include ser-
vices provided by the NHS, other health and social care
agencies, the criminal justice system and informal
carers. In-patient admissions and length of stay will be
recorded for the entire study period. Appropriate unit
costs will be attached to the utilisation data in order to
generate service costs for each participant. Costs will
be compared across the trial conditions and linked to
the primary outcome measure. If costs are lower and
outcomes better, then the intervention will be consid-
ered ‘dominant’. If costs are higher and outcomes better
then incremental cost-effectiveness ratios will be re-
ported and these will indicate the extra cost incurred to
achieve an extra unit of outcome. Uncertainty around
cost-effectiveness estimates will be explored using cost-
effectiveness planes and cost-effectiveness acceptability
curves. Both of these will be generated using 1000 boot-
strapped re-samples from the data. To make sure all key
elements of the economic evaluation are properly re-
ported, the CHEERS checklist will be completed [43].
Research ethics approval and governance
King’s College London is the research sponsor. The trial
will be conducted in accordance with the principles of
the Declaration of Helsinki (current 2013 version). The
study has been reviewed and approved by the London-
Hampstead Research Ethics Committee (+: 13/Lo/0482).
Modifications to the protocol require a formal amend-
ment to the protocol. This will be completed by the Pri-
mary Investigator and Trial Coordinator and approved
by the London-Hampstead Research Ethics Committee.
All changes and amendments to the protocol are super-
vised and approved by the sponsor. Medical Research
Council Guidelines for Good Practice in Clinical Trials
will be followed to ensure the trial integrity and partici-
pants’ safety and wellbeing [44]. The Trial Steering
Committee (TSC) comprises one clinician independent
chair, one senior clinician and a service user. A DMEC
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includes a clinician as independent chair, a senior clin-
ician and statistician.
Discussion
Around a quarter of people suffering from psychotic
conditions continue to experience auditory hallucina-
tions despite adequate drug treatment [45, 46]. Treat-
ment of this problem is a public health priority because
people suffering from distressing voices often have a low
quality of life [47]. Recent developments in treatment
for distressing voices, which focus on the interpersonal
relationship between voice-hearer and their voice, in-
clude a specific cognitive therapy for command halluci-
nations [15], as well as other explicitly relational [48]
and dialogic [49] approaches. AVATAR therapy offers a
unique opportunity to work relationally, through real-
time dialogue with an avatar, created by the hearer as a
representation of their voice. Encouraging pilot data sug-
gest that AVATAR therapy may represent an important
and powerful new tool in the treatment of distressing
voices [19].
The brevity of the therapy and its success in decreasing
the frequency of the voices, their volume, and their nega-
tive impact on individuals’ lives requires both replication
in a methodologically rigorous randomised clinical trial
and an exploration of the possible mechanisms for these
effects on experiences which have failed to respond ad-
equately to antipsychotic medication [20]. Refinements to
the software as well as the impact of the quality of the
match between the creation (including voice and image) of
the avatar are also underway. The trial is funded for 36
months. Final outcome assessment will be completed by
mid-2016 and outcome results will become available by
the end of the same year.
Trial status
The trial started recruitment of participants in November
2013 and it will be open until early 2016.
Abbreviations
AVH: auditory verbal hallucinations; AVATAR: Audio Visual Assisted Therapy
Aid for Refractory auditory hallucinations; BAVQ-R: Beliefs about Voices
Questionnaire Revised version; CONSORT: Consolidated Standards of
Reporting Trials; CTU: Clinical Trials Unit; DASS-21: Depression Anxiety and
Stress Scale; DMEC: Data Monitoring and Ethics Committee; NHS: National
Health Service; ICD: International Classification of Diseases; PIC: Patient
Identification Centre; PSYRATS: Psychotic Symptoms Rating Scale;
SAPS/SANS: Scale for Assessment of Positive and Negative Symptoms;
SC: supportive counselling; TSC: Trial Steering Committee; VAAS: Voice
Acceptance and Action Scale; VPDS: Voice Power Differential Scale;
WT: Welcome Trust.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
TC is the chief investigator, conceived the trial, contributed to the design
and drafted the manuscript. PG is the joint principal investigator for the trial,
conceived the study and contributed to the design and critically reviewed
the manuscript. MRC is the trial coordinator, contributed to the design, and
drafted the manuscript. TW is the therapy coordinator, contributed to the
design, and drafted the manuscript. RE is the trial statistician and is
responsible for the main statistical analysis. PM is the health economist
investigator and will lead the health economic analysis. MF is a member of
the Trial Management Group, contributed to the design and critically
reviewed the manuscript. All authors contributed to the design of the study
and were involved in writing the manuscript. All authors read and approved
the final manuscript.
Acknowledgments
The research is funded by a Wellcome Trust Translation Award (number
09827). The clinical trial is based at King’s College London while further
development of the AVATAR computer-based system is based at the Speech,
Hearing & Phonetic Sciences Department at University College London. The
trial team express their gratitude to Prof. Julian Leff for training and advice
on the delivery of therapy, and to Dr. Mark Huckvale and Dr. Geoffey Williams
for their continued technical support of the AVATAR system. PG is part
funded by the National Institute for Health Research (NIHR) Biomedical
Research Centre at South London and Maudsley NHS Foundation Trust
and King’s College London.
Author details
1Department of Health Service and Population Research, Institute of
Psychiatry, Psychology and Neuroscience, King’s College London, London,
UK. 2Department of Psychology, Institute of Psychiatry, Psychology and
Neuroscience, King’s College London, London, UK. 3Research Department of
Clinical, Educational and Health Psychology University College London,
London, UK. 4Centre for Biostatistics, Institute of Population Health, The
University of Manchester, Manchester Academic Health Science Centre,
London, UK.
Received: 10 April 2015 Accepted: 27 July 2015
References
1. Waters F, Allen P, Aleman A, Fernyhough C, Woodward TS, Badcock JC,
et al. Auditory hallucinations in schizophrenia and nonschizophrenia
populations: a review and integrated model of cognitive mechanisms.
Schizophr Bull. 2012;38(4):683–93. doi:10.1093/schbul/sbs045.
2. Mawson A, Cohen K, Berry K. Reviewing evidence for the cognitive model
of auditory hallucinations: the relationship between cognitive voice
appraisals and distress during psychosis. Clin Psychol Rev. 2010;30(2):248–58.
doi:10.1016/j.cpr.2009.11.006.
3. McCarthy-Jones S, Resnick PJ. Listening to voice: the use of
phenomenology to differentiate malingered from genuine auditory verbal
hallucinations. Int J Law Psychiatry. 2014;37:183–9.
4. Woods A, Jones N, Bernini M, Callard F, Alderson-Day B, Badcock JC, et al.
Interdisciplinary approaches to the phenomenology of auditory verbal
hallucinations. Schizophr Bull. 2014;40:S246–54. doi:10.1093/schbul/sbu003.
5. Thomas N, Hayward M, Peters E, van der Gaag M, Bentall RP, Jenner J, et al.
Psychological therapies for auditory hallucinations (Voices): current status
and key directions for future research. Schizophr Bull. 2014;40:S202–12.
doi:10.1093/schbul/sbu037.
6. Chadwick P, Birchwood M. The omnipotence of voices – a cognitive
approach to auditory hallucinations. Brit J Psychiat. 1994;164:190–201.
doi:10.1192/bjp.164.2.190.
7. Morrison AP, Haddock G, Tarrier N. Intrusive thoughts and auditory
hallucinations: a cognitive approach. Behav Cogn Psychother. 1995;23:265–80.
8. Morrison AP, Haddock G. Cognitive factors in source monitoring
and auditory hallucinations. Psychol Med. 1997;27(3):669–79.
doi:10.1017/S003329179700487x.
9. Morrison AP. The interpretation of intrusions in psychosis: an integrative
cognitive approach to hallucinations and delusions. Behav Cogn
Psychother. 2001;29(3):257–76. doi:10.1017/S1352465801003010.
10. Birchwood M, Meaden A, Trower P, Gilbert P, Plaistow J. The power
and omnipotence of voices: subordination and entrapment by
voices and significant others. Psychol Med. 2000;30(2):337–44.
doi:10.1017/S0033291799001828.
11. Birchwood M, Gilbert P, Gilbert J, Trower P, Meaden A, Hay J, et al.
Interpersonal and role-related schema influence the relationship with the
Craig et al. Trials  (2015) 16:349 Page 8 of 9
dominant ‘voice’ in schizophrenia: a comparison of three models. Psychol
Med. 2004;34:1571–80.
12. Gilbert P, Allan S. Assertiveness, submissive behavior and social-comparison.
Brit J Clin Psychol. 1994;33:295–306.
13. Gilbert P, Birchwood M, Gilbert J, Trower P, Hay J, Murray E, et al. An
exploration of evolved mental mechanisms for dominant and subordinate
behaviour in relation to auditory hallucinations in schizophrenia and critical
thoughts in depression. Psychol Med. 2001;31:1117–27.
14. Paulik G. The role of social schema in the experience of auditory
hallucinations: a systematic review and a proposal for the inclusion of social
schema in a cognitive behavioural model of voice hearing. Clin Psychol
Psychot. 2012;19(6):459–72. doi:10.1002/Cpp.768.
15. Birchwood M, Michail M, Meaden A, Tarrier N, Lewis S, Wykes T, et al.
Cognitive behaviour therapy to prevent harmful compliance with
command hallucinations (COMMAND): a randomised controlled trial. Lancet
Psychiat. 2014;1(1):23–33.
16. Trower P, Birchwood M, Meaden A, Byrne S, Nelson A, Ross K. Cognitive
therapy for command hallucinations: randomised controlled trial. Brit J
Psychiat. 2004;184:312–20. doi:10.1192/bjp.184.4.312.
17. Hayward M. Interpersonal relating and voice hearing: to what extent does
relating to the voice reflect social relating? Psychol Psychother-T.
2003;76:369–83. doi:10.1348/147608303770584737.
18. Hayward M, Overton J, Dorey T, Denney J. Relating therapy for people who
hear voices: a case series. Clin Psychol Psychot. 2009;16(3):216–27.
doi:10.1002/Cpp.615.
19. Leff J, Williams G, Huckvale MA, Arbuthnot M, Leff AP. Computer-assisted
therapy for medication-resistant auditory hallucinations: proof-of-concept
study. Br J Psychiatry. 2013;202:428–33. doi:10.1192/bjp.bp.112.124883.
20. Leff J, Williams G, Huckvale M, Arbuthnot M, Leff AP. Avatar therapy for
persecutory auditory hallucinations: what is it and how does it work?
Psychosis. 2014;6(2):166–76. doi:10.1080/17522439.2013.773457.
21. Mayhew SL, Gilbert P. Compassionate mind training with people who
hear malevolent voices: a case series report. Clin Psychol Psychot.
2008;15(2):113–38.
22. van der Gaag M, Valmaggia LR, Smit F. The effects of individually tailored
formulation-based cognitive behavioural therapy in auditory hallucinations
and delusions: a meta-analysis. Schizophr Res. 2014;156(1):30–7.
doi:10.1016/j.schres.2014.03.016.
23. Freeman D, Dunn G, Garety P, Weinman J, Kuipers E, Fowler D, et al.
Patients’ beliefs about the causes, persistence and control of psychotic
experiences predict take-up of effective cognitive behaviour therapy for
psychosis. Psychol Med. 2013;43(2):269–77.
24. Garety PA, Fowler DG, Freeman D, Bebbington P, Dunn G, Kuipers E.
Cognitive–behavioural therapy and family intervention for relapse
prevention and symptom reduction in psychosis: randomised controlled
trial. Br J Psychiatry. 2008;192(6):412–23. doi:10.1192/bjp.bp.107.043570.
25. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P, Grp C. Extending the
CONSORT statement to randomized trials of nonpharmacologic treatment:
explanation and elaboration. Ann Intern Med. 2008;148(4):295–309.
26. McGuffin P, Farmer A, Harvey I. A polydiagnostic application of operational
criteria in studies of psychotic illness. Arch Gen Psychiatry. 1991;48:764–70.
27. Lewis SW, Tarrier N, Haddock G, Bentall R, Kinderman P, Kingdon D, et al.
The socrates trial: a multicentre, randomised, controlled trial of cognitive-
behaviour therapy in early schizophrenia. Schizophr Res. 2000;41(1):9.
doi:10.1016/S0920-9964(00)90327-X.
28. Haddock G, McCarron J, Tarrier N, Faragher EB. Scales to measure
dimensions of hallucinations and delusions: the psychotic symptom
rating scales (PSYRATS). Psychol Med. 1999;29(4):879–89.
doi:10.1017/S0033291799008661.
29. Chadwick P, Lees S, Birchwood M. The revised Beliefs About
Voices Questionnaire (BAVQ-R). Brit J Psychiat. 2000;177:229–32.
doi:10.1192/bjp.177.3.229.
30. Shawyer F, Ratcliff K, Mackinnon A, Farhall J, Hayes SC, Copolov D. The
Voices Acceptance and Action Scale (VAAS): Pilot data. J Clin Psychol.
2007;63(6):593–606. doi:10.1002/Jclp.20366.
31. Andreasen NC. The scale for the assessment of positive symptoms (SAPS).
Iowa City: The University of Iowa; 1984.
32. Lovibond PF, Lovibond SH. The structure of negative emotional states –
comparison of the Depression Anxiety Stress Scales (DASS) with the Beck
Depression and Anxiety Inventories. Behav Res Ther. 1995;33(3):335–43.
doi:10.1016/0005-7967(94)00075-U.
33. Addington D, Addington J, Matickatyndale E. Assessing depression in
schizophrenia – the Calgary Depression Scale. Brit J Psychiat. 1993;163:39–44.
34. Rosenberg M. Society and the adolescent self-image. Princeton, NJ:
Princeton: University Press; 1965.
35. Priebe S, Huxley P, Knight S, Evans S. Application and results of the
Manchester Short Assessment of Quality of Life (MANSA). Int J Soc Psychiatr.
1999;45(1):7–12. doi:10.1177/002076409904500102.
36. Marsden J, Gossop M, Stewart D, Best D, Farrell M, Lehmann P, et al.
The Maudsley Addiction Profile (MAP): a brief instrument for
assessing treatment outcome. Addiction. 1998;93(12):1857–67.
doi:10.1046/j.1360-0443.1998.9312185711.x.
37. Slater M, Usoh M, Steed A. Depth of presence in virtual environments.
Presence: Teleoperators Virtual Environ. 1994;3:130–44.
38. Freeman D, Pugh K, Green C, Valmaggia L, Dunn G, Garety P. A measure of
state persecutory ideation for experimental studies. J Nerv Ment Dis.
2007;195(9):781–4.
39. Burns DD, Auerbach A. Therapeutic empathy in cognitive-behavioral
therapy: does it really make any difference? In: Salkovskis PM, editor.
Frontiers of cognitive therapy. New York: Guilford Press; 1996. p. 135–64.
40. StataCorp. Stata Statistical Software: Release 13. College Station, TX:
StataCorp LP; 2013.
41. Emsley R, Dunn G, White I. Mediation and moderation of treatment effects
in randomised controlled trials of complex interventions. Stat Methods Med
Res. 2010;19:237–70.
42. Beecham J. Collecting and estimating costs. In: Knapp M, editor. The
economic evaluation of mental health care. Aldershot: Arena; 1995.
43. Husureau D, Drummond M, Petrou S, Carswell K, Moher D, Greenberg D,
et al. Consolidated Health Economic Evaluation Reporting Standards
(CHEERS) statement. BMC Med. 2013;11(80):1–6.
44. Council MR. MRC Guidelines for Good Clinical Practice in Clinical Trials. MRC,
London. 1998. http://www.mrc.ac.uk/documents/pdf/good-clinical-practice-
in-clinical-trials/. Accessed 11 Aug 2015.
45. Aleman A, Laroi F. Insights into hallucinations in schizophrenia: novel
treatment approaches. Expert Rev Neurother. 2011;11(7):1007–15.
doi:10.1586/Ern.11.90.
46. Shergill SS, Murray RM, McGuire PK. Auditory hallucinations: a review
of psychological treatments. Schizophr Res. 1998;32(3):137–50.
doi:10.1016/S0920-9964(98)00052-8.
47. Sommer IEC, Slotema CW, Daskalakis ZJ, Derks EM, Blom JD, van der Gaag
M. The treatment of hallucinations in schizophrenia spectrum disorders.
Schizophr Bull. 2012;38(4):704–14. doi:10.1093/schbul/sbs034.
48. Hayward M, Strauss C, Bogen-Johnston L. Relating therapy for voices (the
R2V study): study protocol for a pilot randomized controlled trial. Trials.
2014;15. Article number 325. doi:10.1186/1745-6215-15-325.
49. Corstens D, Longden E, May R. Talking with voices: exploring what is
expressed by the voices people hear. Psychosis. 2012;4(2):95–104.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Craig et al. Trials  (2015) 16:349 Page 9 of 9
